{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:29:14Z","timestamp":1794508154936,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23KJ1774"],"award-info":[{"award-number":["JP23KJ1774"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06362"],"award-info":[{"award-number":["JP23K06362"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K15315"],"award-info":[{"award-number":["JP21K15315"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03406"],"award-info":[{"award-number":["JP20H03406"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03459"],"award-info":[{"award-number":["JP20H03459"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23H03742"],"award-info":[{"award-number":["JP23H03742"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      CD169\n                      <jats:sup>+<\/jats:sup>\n                      macrophages in lymph nodes (LNs) activate cytotoxic T lymphocytes (CTLs), which play a crucial role in anticancer immunity, through antigen presentation and co-stimulation by CD169. Interferon alpha (IFN\u03b1) is capable of inducing the CD169\n                      <jats:sup>+<\/jats:sup>\n                      phenotype of macrophages; however, its clinical applications have been hindered by pharmacokinetic limitations\u2014low LN distribution and an inability to target macrophages. To overcome these issues, this study genetically fused mouse IFN\u03b1 (mIFN\u03b1) with mannosylated mouse serum albumin (Man-MSA), and investigated the antitumor effects of the hybrid protein (Man-MSA-mIFN\u03b1) or its add-on effects with programmed death-ligand 1 (PD-L1) blockade.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To confirm the possibility of CD169\n                      <jats:sup>+<\/jats:sup>\n                      macrophage-mediated T cell priming, positional information about individual immune cells in LNs of cancer patients was obtained. Traits of Man-MSA-mIFN\u03b1, which was prepared using\n                      <jats:italic>Pichia pastoris<\/jats:italic>\n                      to form the high-mannose structure, were characterized by several physicochemical methods. To evaluate the lymphatic drainage of Man-MSA-mIFN\u03b1, radioiodine or Cy5-labeled Man-MSA-mIFN\u03b1 was subcutaneously administered in mice, and then the radioactivity or fluorescence in LNs was analyzed. CD169-diphtheria toxin (DT) receptor (CD169-DTR) mice in which LN CD169\n                      <jats:sup>+<\/jats:sup>\n                      macrophages can be depleted by DT injection were used to verify whether the antitumor effect of Man-MSA-mIFN\u03b1 is dependent on LN CD169\n                      <jats:sup>+<\/jats:sup>\n                      macrophages.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multiplex tissue imaging predicted close proximity of CD169\n                      <jats:sup>+<\/jats:sup>\n                      macrophages and T cells and positive correlation between the number of CD169\n                      <jats:sup>+<\/jats:sup>\n                      macrophages and T cells in neighborhoods in LNs of cancer patients. Physicochemical analyses showed that Man-MSA-mIFN\u03b1 was formed from the fusion of the intact Man-MSA and mIFN\u03b1. Man-MSA-mIFN\u03b1 efficiently induced the CD169\n                      <jats:sup>+<\/jats:sup>\n                      phenotype of macrophages by its high LN distribution and macrophage-targeting capability, and significantly exerted antitumor activity through CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell activation in the LNs, whereas its antitumor effects were canceled in CD169-DTR mice. Finally, combination therapy with PD-L1 blockade markedly suppressed tumor growth in MB49-bearing mice, which exhibit resistance to PD-L1 blockade monotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The present study successfully designed and developed Man-MSA-mIFN\u03b1, which efficiently induces the CD169\n                      <jats:sup>+<\/jats:sup>\n                      phenotype in LN macrophages, contributing to the antitumor immunity. The findings suggest that our novel strategy targeting CD169\u207a macrophages could be a promising immunotherapy for cancer patients who are unresponsive to immune checkpoint inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02324-8","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:04:49Z","timestamp":1746230689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages"],"prefix":"10.1186","volume":"24","author":[{"given":"Ryo","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Minayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshiro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Oniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Saruwatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Komohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"2324_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pros.24068","volume":"81","author":"Y Yang","year":"2021","unstructured":"Yang Y, Attwood K, Bshara W, Mohler JL, Guru K, Xu B, Kalinski P, Chatta G. High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate. 2021;81:20\u20138.","journal-title":"Prostate"},{"key":"2324_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint Blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"2324_CR3","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"2324_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.immuni.2010.12.011","volume":"34","author":"K Asano","year":"2011","unstructured":"Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011;34:85\u201395.","journal-title":"Immunity"},{"key":"2324_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/path.4720","volume":"239","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Li JQ, Jiang ZZ, Li L, Wu Y, Zheng L. CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma. J Pathol. 2016;239:231\u201341.","journal-title":"J Pathol"},{"key":"2324_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2012.06.063","volume":"224","author":"YS Xiong","year":"2012","unstructured":"Xiong YS, Wu AL, Lin QS, Yu J, Li C, Zhu L, Zhong RQ. Contribution of monocytes Siglec-1 in stimulating T cells proliferation and activation in atherosclerosis. Atherosclerosis. 2012;224:58\u201365.","journal-title":"Atherosclerosis"},{"key":"2324_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/cas.12212","volume":"104","author":"K Ohnishi","year":"2013","unstructured":"Ohnishi K, Komohara Y, Saito Y, Miyamoto Y, Watanabe M, Baba H, Takeya M. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci. 2013;104:1237\u201344.","journal-title":"Cancer Sci"},{"key":"2324_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/cas.13565","volume":"109","author":"T Asano","year":"2018","unstructured":"Asano T, Ohnishi K, Shiota T, Motoshima T, Sugiyama Y, Yatsuda J, Kamba T, Ishizaka K, Komohara Y. CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. Cancer Sci. 2018;109:1723\u201330.","journal-title":"Cancer Sci"},{"key":"2324_CR9","doi-asserted-by":"publisher","first-page":"1848067","DOI":"10.1080\/2162402X.2020.1848067","volume":"9","author":"F Bj\u00f6rk Gunnarsdottir","year":"2020","unstructured":"Bj\u00f6rk Gunnarsdottir F, Auoja N, Bendahl PO, Ryd\u00e9n L, Fern\u00f6 M, Leandersson K. Co-localization of CD169(+) macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression. Oncoimmunology. 2020;9:1848067.","journal-title":"Oncoimmunology"},{"key":"2324_CR10","doi-asserted-by":"publisher","first-page":"636751","DOI":"10.3389\/fonc.2021.636751","volume":"11","author":"K Kumamoto","year":"2021","unstructured":"Kumamoto K, Tasaki T, Ohnishi K, Shibata M, Shimajiri S, Harada M, Komohara Y, Nakayama T. CD169 expression on lymph node macrophages predicts in patients with gastric Cancer. Front Oncol. 2021;11:636751.","journal-title":"Front Oncol"},{"key":"2324_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/cas.12929","volume":"107","author":"K Ohnishi","year":"2016","unstructured":"Ohnishi K, Yamaguchi M, Erdenebaatar C, Saito F, Tashiro H, Katabuchi H, Takeya M, Komohara Y. Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma. Cancer Sci. 2016;107:846\u201352.","journal-title":"Cancer Sci"},{"key":"2324_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/pin.12736","volume":"68","author":"H Takeya","year":"2018","unstructured":"Takeya H, Shiota T, Yagi T, Ohnishi K, Baba Y, Miyasato Y, Kiyozumi Y, Yoshida N, Takeya M, Baba H, Komohara Y. High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer. Pathol Int. 2018;68:685\u201393.","journal-title":"Pathol Int"},{"key":"2324_CR13","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/2326-6066.CIR-14-0180","volume":"3","author":"Y Saito","year":"2015","unstructured":"Saito Y, Ohnishi K, Miyashita A, Nakahara S, Fujiwara Y, Horlad H, Motoshima T, Fukushima S, Jinnin M, Ihn H, et al. Prognostic significance of CD169\u2009+\u2009Lymph node sinus macrophages in patients with malignant melanoma. Cancer Immunol Res. 2015;3:1356\u201363.","journal-title":"Cancer Immunol Res"},{"key":"2324_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/eji.202149575","volume":"52","author":"H Rincon-Arevalo","year":"2022","unstructured":"Rincon-Arevalo H, Aue A, Ritter J, Szelinski F, Khadzhynov D, Zickler D, Stefanski L, Lino AC, K\u00f6rper S, Eckardt KU, et al. Altered increase in STAT1 expression and phosphorylation in severe COVID-19. Eur J Immunol. 2022;52:138\u201348.","journal-title":"Eur J Immunol"},{"key":"2324_CR15","doi-asserted-by":"publisher","first-page":"e2209910","DOI":"10.1002\/adma.202209910","volume":"35","author":"F Chen","year":"2023","unstructured":"Chen F, Li T, Zhang H, Saeed M, Liu X, Huang L, Wang X, Gao J, Hou B, Lai Y, et al. Acid-Ionizable Iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of Cancer. Adv Mater. 2023;35:e2209910.","journal-title":"Adv Mater"},{"key":"2324_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.omtn.2019.04.016","volume":"16","author":"J Hu","year":"2019","unstructured":"Hu J, Xu J, Li M, Zhang Y, Yi H, Chen J, Dong L, Zhang J, Huang Z. Targeting lymph node sinus macrophages to inhibit lymph node metastasis. Mol Ther Nucleic Acids. 2019;16:650\u201362.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2324_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40843-017-9053-y","volume":"60","author":"G Wang","year":"2017","unstructured":"Wang G, Hu J, Gao W. Tuning the molecular size of site-specific interferon-polymer conjugate for optimized antitumor efficacy. Sci China Mater. 2017;60:563\u201370.","journal-title":"Sci China Mater"},{"key":"2324_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1172\/JCI81083","volume":"126","author":"TJ Moyer","year":"2016","unstructured":"Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest. 2016;126:799\u2013808.","journal-title":"J Clin Invest"},{"key":"2324_CR19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/RLU.0000000000003309","volume":"45","author":"R Valhondo-Rama","year":"2020","unstructured":"Valhondo-Rama R, S\u00e1nchez Izquierdo N, Tapias Mesa A, Perissinotti A, Vidal-Sicart S. Comparison of 99mTc-Tilmanocept and hybrid indocyanine Green-99mTc-Albumin nanocolloid drainage in a patient with melanoma in the scalp. Clin Nucl Med. 2020;45:977\u20139.","journal-title":"Clin Nucl Med"},{"key":"2324_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jconrel.2010.03.010","volume":"145","author":"K Hirata","year":"2010","unstructured":"Hirata K, Maruyama T, Watanabe H, Maeda H, Nakajou K, Iwao Y, Ishima Y, Katsumi H, Hashida M, Otagiri M. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. J Control Release. 2010;145:9\u201316.","journal-title":"J Control Release"},{"key":"2324_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1124\/jpet.114.219493","volume":"352","author":"H Maeda","year":"2015","unstructured":"Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VT, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, et al. Polythiol-containing, Recombinant mannosylated-albumin is a superior CD68+\/CD206\u2009+\u2009Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J Pharmacol Exp Ther. 2015;352:244\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"2324_CR22","doi-asserted-by":"publisher","first-page":"2104136","DOI":"10.1002\/adfm.202104136","volume":"31","author":"Y Mizuta","year":"2021","unstructured":"Mizuta Y, Maeda H, Ishima Y, Minayoshi Y, Ichimizu S, Kinoshita R, Fujita I, Kai T, Hirata K, Nakamura T, et al. A mannosylated, pegylated albumin as a drug delivery system for the treatment of Cancer stroma cells. Adv Funct Mater. 2021;31:2104136.","journal-title":"Adv Funct Mater"},{"key":"2324_CR23","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","volume":"16","author":"S Black","year":"2021","unstructured":"Black S, Phillips D, Hickey JW, Kennedy-Darling J, Venkataraaman VG, Samusik N, Goltsev Y, Sch\u00fcrch CM, Nolan GP. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc. 2021;16:3802\u201335.","journal-title":"Nat Protoc"},{"key":"2324_CR24","unstructured":"Glass G. Papin Ja Fau - Mandell JW, Mandell JW: SIMPLE: a sequential immunoperoxidase labeling and erasing method."},{"key":"2324_CR25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1023\/A:1013391001141","volume":"18","author":"H Watanabe","year":"2001","unstructured":"Watanabe H, Yamasaki K, Kragh-Hansen U, Tanase S, Harada K, Suenaga A, Otagiri M. In vitro and in vivo properties of Recombinant human serum albumin from Pichia pastoris purified by a method of short processing time. Pharm Res. 2001;18:1775\u201381.","journal-title":"Pharm Res"},{"key":"2324_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/cas.13137","volume":"108","author":"Y Komohara","year":"2017","unstructured":"Komohara Y, Ohnishi K, Takeya M. Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses. Cancer Sci. 2017;108:290\u20135.","journal-title":"Cancer Sci"},{"key":"2324_CR27","doi-asserted-by":"publisher","first-page":"107523","DOI":"10.1016\/j.celrep.2020.107523","volume":"31","author":"CR Stoltzfus","year":"2020","unstructured":"Stoltzfus CR, Filipek J, Gern BH, Olin BE, Leal JM, Wu Y, Lyons-Cohen MR, Huang JY, Paz-Stoltzfus CL, Plumlee CR, et al. CytoMAP: A Spatial analysis toolbox reveals features of myeloid cell organization in lymphoid tissues. Cell Rep. 2020;31:107523.","journal-title":"Cell Rep"},{"key":"2324_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11307-015-0851-7","volume":"17","author":"C Cilliers","year":"2015","unstructured":"Cilliers C, Liao J, Atangcho L, Thurber GM. Residualization rates of Near-Infrared dyes for the rational design of molecular imaging agents. Mol Imaging Biol. 2015;17:757\u201362.","journal-title":"Mol Imaging Biol"},{"key":"2324_CR29","doi-asserted-by":"publisher","first-page":"615603","DOI":"10.3389\/fimmu.2020.615603","volume":"11","author":"N Zanin","year":"2020","unstructured":"Zanin N, Viaris de Lesegno C, Lamaze C, Blouin CM. Interferon receptor trafficking and signaling: journey to the cross roads. Front Immunol. 2020;11:615603.","journal-title":"Front Immunol"},{"key":"2324_CR30","doi-asserted-by":"crossref","unstructured":"Krieckaert CL, Bartelds GM, Wolbink GJ. Therapy: Immunogenicity of biologic therapies-we need tolerance. In Nat Rev Rheumatol. Volume 6. United States2010: 558\u2013559.","DOI":"10.1038\/nrrheum.2010.153"},{"key":"2324_CR31","doi-asserted-by":"publisher","first-page":"14648","DOI":"10.1038\/s41598-018-32817-0","volume":"8","author":"J Nilsen","year":"2018","unstructured":"Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT. Human and mouse albumin bind their respective neonatal Fc receptors differently. Sci Rep. 2018;8:14648.","journal-title":"Sci Rep"},{"key":"2324_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/jir.2018.0066","volume":"38","author":"S Jacobs","year":"2018","unstructured":"Jacobs S, Wavreil F, Schepens B, Gad HH, Hartmann R, Rocha-Pereira J, Neyts J, Saelens X, Michiels T. Species specificity of type III interferon activity and development of a sensitive Luciferase-Based bioassay for quantitation of mouse interferon-\u03bb. J Interferon Cytokine Res. 2018;38:469\u201379.","journal-title":"J Interferon Cytokine Res"},{"key":"2324_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/glycob\/cwj077","volume":"16","author":"EP McGreal","year":"2006","unstructured":"McGreal EP, Rosas M, Brown GD, Zamze S, Wong SY, Gordon S, Martinez-Pomares L, Taylor PR. The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology. 2006;16:422\u201330.","journal-title":"Glycobiology"},{"key":"2324_CR34","doi-asserted-by":"publisher","first-page":"765034","DOI":"10.3389\/fimmu.2021.765034","volume":"12","author":"HJP van der Zande","year":"2021","unstructured":"van der Zande HJP, Nitsche D, Schlautmann L, Guigas B, Burgdorf S. The mannose receptor: from endocytic receptor and biomarker to regulator of (Meta)Inflammation. Front Immunol. 2021;12:765034.","journal-title":"Front Immunol"},{"key":"2324_CR35","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365\u201386.","journal-title":"Theranostics"},{"key":"2324_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.niox.2020.03.003","volume":"98","author":"YV Langle","year":"2020","unstructured":"Langle YV, Balarino NP, Belgorosky D, Cresta Morgado PD, Sandes EO, Marino L, Bilbao ER, Zambrano M, Lodillinsky C, Eij\u00e1n AM. Effect of nitric oxide Inhibition in Bacillus Calmette-Guerin bladder cancer treatment. Nitric Oxide. 2020;98:50\u20139.","journal-title":"Nitric Oxide"},{"key":"2324_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41590-021-01120-y","volume":"23","author":"M Bruchard","year":"2022","unstructured":"Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, et al. Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nat Immunol. 2022;23:262\u201374.","journal-title":"Nat Immunol"},{"key":"2324_CR38","doi-asserted-by":"publisher","first-page":"110129","DOI":"10.1016\/j.intimp.2023.110129","volume":"120","author":"AA Mathew","year":"2023","unstructured":"Mathew AA, Zakkariya ZT, Ashokan A, Manohar M, Keechilat P, Nair SV, Koyakutty M. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor. Int Immunopharmacol. 2023;120:110129.","journal-title":"Int Immunopharmacol"},{"key":"2324_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"2324_CR40","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3389\/fimmu.2018.02100","volume":"9","author":"C Grasselly","year":"2018","unstructured":"Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C. The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is Model-Dependent. Front Immunol. 2018;9:2100.","journal-title":"Front Immunol"},{"key":"2324_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423\u201331.","journal-title":"Pharm World Sci"},{"key":"2324_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrd4608","volume":"14","author":"NL Trevaskis","year":"2015","unstructured":"Trevaskis NL, Kaminskas LM, Porter CJ. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14:781\u2013803.","journal-title":"Nat Rev Drug Discov"},{"key":"2324_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0168-3659(97)00104-1","volume":"50","author":"VS Trubetskoy","year":"1998","unstructured":"Trubetskoy VS, Whiteman KR, Torchilin VP, Wolf GL. Massage-induced release of subcutaneously injected liposome-encapsulated drugs to the blood. J Control Release. 1998;50:13\u20139.","journal-title":"J Control Release"},{"key":"2324_CR44","first-page":"390","volume":"7","author":"V Bocci","year":"1988","unstructured":"Bocci V, Pessina GP, Paulesu L, Nicoletti C. The lymphatic route. VI. Distribution of Recombinant interferon-alpha 2 in rabbit and pig plasma and lymph. J Biol Response Mod. 1988;7:390\u2013400.","journal-title":"J Biol Response Mod"},{"key":"2324_CR45","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","volume":"55","author":"BW MacNabb","year":"2022","unstructured":"MacNabb BW, Tumuluru S, Chen X, Godfrey J, Kasal DN, Yu J, Jongsma MLM, Spaapen RM, Kline DE, Kline J. Dendritic cells can prime anti-tumor CD8(+) T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55:982\u2013e997988.","journal-title":"Immunity"},{"key":"2324_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000337007","volume":"4","author":"EE Gray","year":"2012","unstructured":"Gray EE, Cyster JG. Lymph node macrophages. J Innate Immun. 2012;4:424\u201336.","journal-title":"J Innate Immun"},{"key":"2324_CR47","doi-asserted-by":"publisher","first-page":"113966","DOI":"10.1016\/j.addr.2021.113966","volume":"178","author":"M Zhu","year":"2021","unstructured":"Zhu M. Immunological perspectives on Spatial and Temporal vaccine delivery. Adv Drug Deliv Rev. 2021;178:113966.","journal-title":"Adv Drug Deliv Rev"},{"key":"2324_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","volume":"131","author":"EH Pilkington","year":"2021","unstructured":"Pilkington EH, Suys EJA, Trevaskis NL, Wheatley AK, Zukancic D, Algarni A, Al-Wassiti H, Davis TP, Pouton CW, Kent SJ, Truong NP. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021;131:16\u201340.","journal-title":"Acta Biomater"},{"key":"2324_CR49","doi-asserted-by":"publisher","first-page":"109329","DOI":"10.1016\/j.clim.2023.109329","volume":"250","author":"N Sakumura","year":"2023","unstructured":"Sakumura N, Yokoyama T, Usami M, Hosono Y, Inoue N, Matsuda Y, Tasaki Y, Wada T. CD169 expression on monocytes as a marker for assessing type I interferon status in pediatric inflammatory diseases. Clin Immunol. 2023;250:109329.","journal-title":"Clin Immunol"},{"key":"2324_CR50","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/10717544.2018.1464083","volume":"25","author":"Y Minayoshi","year":"2018","unstructured":"Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, et al. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and Immunomodulatory actions. Drug Deliv. 2018;25:1067\u201377.","journal-title":"Drug Deliv"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02324-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:03:44Z","timestamp":1746273824000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02324-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02324-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4946728\/v1","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the Institutional Review Board of Kumamoto University (#1169) in accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki. Paraffin-embedded LN samples were prepared from specimens obtained from patients diagnosed with colorectal cancer that were surgically resected at Izumi General Hospital (Izumi, Kagoshima, Japan). Written informed consent was obtained from all patients, and the study design was approved by the review board (#57). The need for individual patient consent for inclusion in the study was waived by the Institutional Review Board of Kumamoto University (#1169). All animal experiments were conducted using procedures approved by the experimental animal ethics committee at Kumamoto University (A2021-021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}